Cryptococcal Meningitis Reported With Fingolimod Treatment
Case Series
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 3, 2021
- Accepted in final form January 19, 2022
- First Published March 22, 2022.
Author Disclosures
- Maurizio Del Poeta, MD (maurizio.delpoeta{at}stonybrook.edu),
- Brian J. Ward, MDCM (brian.ward{at}mcgill.ca),
- Benjamin Greenberg, MD, MHS, FANA, FAAN, CRND (benjamin.greenberg{at}utsouthwestern.edu),
- Bernhard Hemmer, MD (hemmer{at}tum.de),
- Bruce A.C. Cree, MD, PhD (bruce.cree{at}ucsf.edu),
- Sreelatha Komatireddy, MSc, PhD (sreelatha.komatireddy{at}novartis.com),
- Jitendriya Mishra, MPharm, PhD (jitendriya.mishra{at}novartis.com),
- Roseanne Sullivan, PharmD (roseanne.sullivan{at}novartis.com),
- Ajay Kilaru, MD (ajay.kilaru{at}novartis.com),
- Alan Moore, MSc Biometry (alan.moore{at}novartis.com),
- Thomas Hach, MD (thomas.hach{at}novartis.com) and
- Joseph R. Berger, MD, FACP, FAAN, FANA
- Maurizio Del Poeta, MD (maurizio.delpoeta{at}stonybrook.edu),
Maurizio Del Poeta is a cofounder and Chief Scientific Officer (CSO) of MicroRid Technologies, Inc.
NONE
NONE
JBC (editorial board member)
1) US No. 60/802,678 New Methods for Diagnosis and Treatment of Fungal Infections. Filed 09/01/2010 2) US No. 62/058,622 Glucosylceramide as a vaccine for fungal infection  Filed 10/01/2014 3) US No. 62/088,914 Antifungal targeting the synthesis of fungal sphingolipids. Filed 12/08/2014 4) US No. 62/192,459 New antifungals against fungal sphingolipids. Filed 07/14/2015 5) US No. 62/372,894 Vaccine compositions against pathogenic fungi. Filed 8/10/2016 6) US No. 62/473,742 Inhibiting fungal ceramide synthase as antifungal treatment. Filed 07/26/2016. 7) US No. 15/534,353. Antifungals targeting the synthesis of fungal sphingolipids. Filed 06/08/17. 8) US No. 62/521,069 Anti-Fungal Compounds Targeting the Synthesis of Fungal Sphingolipids. Filed 8/16/18. 9) US No 15/673,937 Vaccine compositions against pathogenic fungi and methods for use thereof. Filed 08/10/2017 10) US No. 16/495,605 Methods of inhibiting fungal ceramide synthase for treatment of cryptococcus neoformans infection. File 09/19/19
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brian J. Ward, MDCM (brian.ward{at}mcgill.ca),
Serve on expert committee for Novartis to review infectious disease complications of disease-modifying therapies
NONE
Occasional speaker fees for talks related to infectious diseases and vaccine use in people taking of disease-modifying therapies and vaccine use
NONE
1) Non-binding influenza hemagglutinin proteins as improved vaccine antigens 2) Attenuated Salmonella Typhimurium-vectored vaccine for C. parvum 3) Attenuated Salmonella Typhimurium-vectored vaccine for Schistosoma mansoni prevention and treatment
NONE
Serve as medical officer for Medicago Inc since 2009, a biotechnology company making vaccines and monoclonal antibodies in plants (no commercial products)
Serve as an ad hoc consultant for Novartis to address questions from practitioners related to infectious disease complications of disease-modifying therapies
NONE
NONE
NONE
1) Medicago Inc: Academic-Industry award for studies related to plant-based virus-like particle vaccines 2) CArrier Therapeutics: Academic-Industry award for studies related to oral vaccine delivery
1) GlycoNet: CIHR Netwok of Excellence, principal investigaor 2021-2023 2) Canadian Immunization Research Network: CIRN Network, principal investigator 2021-2023
NONE
Hewitt Foundation: principal investigator 2021-2023
NONE
NONE
NONE
NONE
NONE
NONE
- Benjamin Greenberg, MD, MHS, FANA, FAAN, CRND (benjamin.greenberg{at}utsouthwestern.edu),
NONE
NONE
NONE
NONE
Dr. Greenberg has filed patents on the use of antibody biology in multiple sclerosis
Transverse Myelitis, UpToDate
NONE
Novartis, Alexion, EMD Serono, Genentech, Horizon Therapeutics, Signant Health, IQVIA, PRIME ED, Immunovant, Sanofi/Genzyme, Rubin Anders
NONE
NONE
NONE
CLENE Nanomedicine, Anokion
NIH RO1 NS071463, Co-investigator 2012-14, PCORI, PI, 2013-2020
Unviersity of Texas Southwestern
Guthy Jackson Foundation, Siegel Rare Neuroimmune Association, National MS Society
NONE
NONE
NONE
NONE
NONE
Expert witness in patent litigation involving Mylan
- Bernhard Hemmer, MD (hemmer{at}tum.de),
Advisory Boards for Novartis, he has served as DSMB member for AllergyCare, TG Therapeutics and Polpharma Biologics
Me or my institution have received speaker honoraria from Desitin
NONE
Editorial board member of Experimental Neurology and Multiple sclerosis Journal
I hold part of two patents; one for the detection of antibodies and T cells against KIR4.1 in a subpopulati on of MS patients and one for genetic determinants of neutralizing antibodies to interferon beta
NONE
NONE
NONE
NONE
NONE
NONE
Regeneron - not related
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bruce A.C. Cree, MD, PhD (bruce.cree{at}ucsf.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Novartis, Sanofi, TG Therapeutics and Therini
NONE
NONE
NONE
Genentech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sreelatha Komatireddy, MSc, PhD (sreelatha.komatireddy{at}novartis.com),
NONE
NONE
NONE
NONE
NONE
NONE
Employee of Novartis Healthcare Private Limited, India
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jitendriya Mishra, MPharm, PhD (jitendriya.mishra{at}novartis.com),
NONE
NONE
NONE
NONE
NONE
NONE
Novartis Healthcare Pvt. Ltd., Hyderabad, India., 7 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roseanne Sullivan, PharmD (roseanne.sullivan{at}novartis.com),
NONE
NONE
NONE
NONE
NONE
NONE
Novartis Pharmaceutical Company Sr. Medical Safety Lead 4 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ajay Kilaru, MD (ajay.kilaru{at}novartis.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alan Moore, MSc Biometry (alan.moore{at}novartis.com),
NONE
NONE
NONE
NONE
NONE
NONE
Novartis Pharma AG, Basel 35 years employed
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have shares in Novartis AG, Basel
NONE
NONE
- Thomas Hach, MD (thomas.hach{at}novartis.com) and
NONE
NONE
NONE
NONE
NONE
NONE
Employed by Novartis Pharma AG, Basel.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Stock of Novartis Pharma AG
NONE
NONE
- Joseph R. Berger, MD, FACP, FAAN, FANA
Dr. Berger has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for (1) MAPI and (2) ExcisionBio.
NONE
NONE
Dr. Berger has received personal compensation an Editor, Associate Editor, or Editorial Advisory Board Member for (1) WebMD 2019-present.
NONE
NONE
NONE
Dr. Berger has received personal compensation for serving as a Consultant for (1) Celegene/BMS; (2) Cellevolve; (3) EMD Serono/Merck; (4) Genentech; (5) Genzyme; (6) Janssen/J&J; (7) Morphic; (8) NeuVIR; (9) Novartis; (10) Roche; (11) Sanofi; (12) Takeda; (13) TG Therapeutics.
NONE
NONE
NONE
The institution of Dr. Berger has received research support from Biogen and from Genentech/Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, defense of patent, 2021
- From the Department of Microbiology and Immunology (M.D.P.), Stony Brook University; Division of Infectious Diseases (M.D.P.), School of Medicine, Stony Brook University; Veterans Affairs Medical Center (M.D.P.), Northport, NY; Infectious Diseases Division (B.J.W.), Research Institute of the McGill University Health Centre, Montreal, QC, Canada; University of Texas Southwestern Medical Center (B.G.), Department of Neurology, Dallas, TX; Department of Neurology (B.H.), Klinikum Rechts der Isar, Technical University of Munich; Munich Cluster for Systems Neurology (SyNergy) (B.H.), Germany; UCSF Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Novartis Healthcare Pvt. Ltd. (S.K., J.M.), Hyderabad, India; Novartis Pharmaceuticals Corporation (R.S.), East Hanover, NJ; Novartis Pharma AG (A.K., A.M., T.H.), Basel, Switzerland; and Department of Neurology (J.R.B.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Correspondence
Dr. Berger joseph.berger{at}pennmedicine.upenn.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.